SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of March 2020
Commission File Number 001-37410
ESSA Pharma Inc.
(Translation of registrant’s name into English)
Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-Fx Form 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):¨
EXPLANATORY NOTE
The following exhibits included herein were filed by the Registrant with the Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval on the dates noted below:
1. | Exhibit 99.1 | News Release date March 31, 2020: ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update |
This report on Form 6-K shall be incorporated by reference into the registrant’s Registration Statements on Form F-3 (File No. 333-222654 and File No. 333-234136) and Form S-8 (File No. 333-225056) under the Securities Act of 1933, as amended.
EXHIBITS INCLUDED AS PART OF THIS REPORT
Exhibit | |
99.1 | News Release date March 31, 2020: ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ESSAPHARMAINC. | ||||||
(Registrant) | ||||||
Date: March 31, 2020. | By: | /S/ DAVIDWOOD | ||||
Name: Title: | David Wood Chief Financial Officer |